Form 4 for DFTX Definium Therapeutics, Inc.
Accepted 2022-08-17 00:00:00 ET · period of report 2022-08-16 · accession 0000899243-22-029072 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-08-17 | 2022-08-16 | DFTX | Barrow Robert | CEO, Dir | S - Sale | $0.68 | -20.4K | 3.86M | -0.5% | -$13.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2022-08-16 | S | D | 20,350 | $0.68 | 3,860,438 | D | — | — | (F2) The Common Shares were sold in one transaction at a price of $0.87 CAD Dollars. This represents the price in United States Dollars using the conversion rate on August 16, 2022. |